Abstract: The present disclosure provides a method and device for controlling a touch screen, and an electronic device. The method includes: applying a first driving voltage to a voltage input terminal of the bridge, and obtaining a first voltage difference between a first voltage output terminal and a second voltage output terminal of the bridge corresponding to the first driving voltage; determining a first equivalent resistance value of the bridge corresponding to the first driving voltage at a current temperature according to the first driving voltage and a preset equation; determining a first compensation voltage value corresponding to the current temperature according to the first equivalent resistance value, the first voltage difference, and a preset formula; determining whether to trigger a touch unit corresponding to the bridge according to the first voltage difference and the first compensation voltage value.

Abstract: An air purifier and a purifying method are provided. The air purifier includes a housing, a sterilization and ozone-generating unit, a physical filter, a first ozone-removing unit, and a cover. The housing has a sidewall and a bottom surface to define a processing space, wherein an upper end of the housing has an air inlet and the sidewall has an air outlet. The sterilization and ozone-generating unit is disposed in the processing space. The physical filter is disposed in the processing space, extends along the sidewall, and surrounds the sterilization and ozone-generating unit. The first ozone-removing unit is disposed between the physical filter and the sidewall. The cover is openably disposed at the air inlet.

Abstract: The application discloses a display panel and a display device. The display panel includes a substrate. The substrate includes a bonding region and a bend region connected to the bonding region. The substrate further includes a support block disposed corresponding to the bend region and the bonding region and disposed on a side of the substrate facing away from a display surface. The maximum thickness of the support block located in the bonding region is greater than the maximum thickness of the support block located in the bend region.

Abstract: A modularized respiratory treatment apparatus provides various respiratory pressure treatments. The apparatus may be formed by discrete connectable modules such as a flow generator module, alarm module and/or humidifier module. Each module may include its own external casing or housing to independently retain or enclose the respective components that serve the function of the module. Different modules may be adapted with different components and functionalities and may be readily coupled using standardized gas and electrical connection configurations that have flow and communication paths that extend through the modules. When coupled, operation of the respiratory treatment apparatus may be controlled by detection of different modules, such as the alarm module that generates visual and/or audible alarms based on detected conditions, so as to selectively enable or disable different respiratory treatments.

Abstract: A carbonized material, a device for removing ozone, and a method for removing ozone are provided. The carbonized material has at least a carbonyl-containing group, alkylol group, and carbon having sp2 hybrid orbital. In particular, the at least one carbonyl-containing group has a carbon content from 10 atom % to 30 atom %, based on the total carbon atoms of the at least one carbonyl-containing group, the at least one alkylol group, and the at least one carbon having sp2 hybrid orbital.

Abstract: A modularized respiratory treatment apparatus provides various respiratory pressure treatments. The apparatus may be formed by discrete connectable modules such as a flow generator module, alarm module and/or humidifier module. Each module may include its own external casing or housing to independently retain or enclose the respective components that serve the function of the module. Different modules may be adapted with different components and functionalities and may be readily coupled using standardized gas and electrical connection configurations that have flow and communication paths that extend through the modules. When coupled, operation of the respiratory treatment apparatus may be controlled by detection of different modules, such as the alarm module that generates visual and/or audible alarms based on detected conditions, so as to selectively enable or disable different respiratory treatments.

Abstract: A carbonized material, a device for removing ozone, and a method for removing ozone are provided. The carbonized material has at least a carbonyl-containing group, alkylol group, and carbon having sp2 hybrid orbital. In particular, the at least one carbonyl-containing group has a carbon content from 10 atom % to 30 atom %, based on the total carbon atoms of the at least one carbonyl-containing group, the at least one alkylol group, and the at least one carbon having sp2 hybrid orbital.

Abstract: A modularized respiratory treatment apparatus provides various respiratory pressure treatments. The apparatus may be formed by discrete connectable modules such as a flow generator module, alarm module and/or humidifier module. Each module may include its own external casing or housing to independently retain or enclose the respective components that serve the function of the module. Different modules may be adapted with different components and functionalities and may be readily coupled using standardized gas and electrical connection configurations that have flow and communication paths that extend through the modules. When coupled, operation of the respiratory treatment apparatus may be controlled by detection of different modules, such as the alarm module that generates visual and/or audible alarms based on detected conditions, so as to selectively enable or disable different respiratory treatments.

Abstract: A backup method and a backup system are provided by the present disclosure. The method includes following steps: identifying the group the electronic device belongs when the backup device receives a backup request from an electronic device; receiving the data from the electronic device after identifying the group which the electronic device belong to; generating a unique mark to mark the received data; comparing a mark of the received data with the marks of the data already stored in the storage space assigned to the group which the electronic device belongs; determining whether the received data already exists in the storage space; storing the received data into the storage space assigned to the group which the electronic device belongs to only when the data from the electronic device does not exists in the storage space.

Abstract: A modularized respiratory treatment apparatus provides various respiratory pressure treatments. The apparatus may be formed by discrete connectable modules such as a flow generator module, alarm module and/or humidifier module. Each module may include its own external casing or housing to independently retain or enclose the respective components that serve the function of the module. Different modules may be adapted with different components and functionalities and may be readily coupled using standardized gas and electrical connection configurations that have flow and communication paths that extend through the modules. When coupled, operation of the respiratory treatment apparatus may be controlled by detection of different modules, such as the alarm module that generates visual and/or audible alarms based on detected conditions, so as to selectively enable or disable different respiratory treatments.

Abstract: A backup method and a backup system are provided by the present disclosure. The method includes following steps: identifying the group the electronic device belongs when the backup device receives a backup request from an electronic device; receiving the data from the electronic device after identifying the group which the electronic device belong to; generating a unique mark to mark the received data; comparing a mark of the received data with the marks of the data already stored in the storage space assigned to the group which the electronic device belongs; determining whether the received data already exists in the storage space; storing the received data into the storage space assigned to the group which the electronic device belongs to only when the data from the electronic device does not exists in the storage space.

Abstract: A modularized respiratory treatment apparatus provides various respiratory pressure treatments. The apparatus may be formed by discrete connectable modules such as a flow generator module, alarm module and/or humidifier module. Each module may include its own external casing or housing to independently retain or enclose the respective components that serve the function of the module. Different modules may be adapted with different components and functionalities and may be readily coupled using standardized gas and electrical connection configurations that have flow and communication paths that extend through the modules. When coupled, operation of the respiratory treatment apparatus may be controlled by detection of different modules, such as the alarm module that generates visual and/or audible alarms based on detected conditions, so as to selectively enable or disable different respiratory treatments.

Abstract: The invention provides a method of controlling obesity or type two diabetes in a human. In accordance with the inventive method, the constitutive androstane receptor (CAR) is agonized within the human, which effectively controls obesity or type two diabetes.

Abstract: An electronic device (100) employs a viewing window (10), which includes a transparent substrate (11), an ink layer (12) and a metal layer (14). The ink layer is made of semitransparent ink or transparent matte ink. The ink layer is formed on the substrate and partially covers the substrate; and the metal layer is formed on the ink layer.

Abstract: The present invention relates to a method of carbamylating an erythropoietin such that the resulting carbamylated erythropoietin has less that about 10% free primary amines on the lysines and the N-terminal amino acids, is not digested when exposed to Lys-C proteolysis, exhibits no erythropoietic activity in a TF-1 or UT-7/EPOR cell viability assay at a concentration of 1 ?g/ml, and demonstrates a static sciatic index of less than about 0.65 within a Sciatic Nerve Assay. Additionally, the invention is related to pharmaceutical compositions containing carbamylated erythropoietins of the invention and the use of the pharmaceutical compositions for the treatment of conditions and diseases of excitable tissues.

Abstract: In accordance with the present invention, there are provided methods for modulating Phase II conjugating enzymes such as, for example, UGTs. Phase II conjugating enzymes such as UGTs function in concert with Phase I monooxygenase enzymes such as cytochrome P450 enzymes (CYPs) to eliminate steroids and xenobiotics. Nuclear receptors SXR/PXR and CAR are xenosensors regulating expression of CYP genes such as CYP3A and 2B. The ability of this group of receptors to regulate expression of UGT in response to steroids and/or xenobiotics provides novel approaches for direct regulation/activation of a glucuronidation pathway, thereby providing methods to achieve physiologic homeostasis with respect to steroids and/or xenobiotics. SXR/PXR and CAR regulation/activation of UGT represents the first evidence of receptors that can transduce/transactivate both Phase I and Phase II adaptive hepatic response. In another aspect, the present invention also provides transgenic rodents expressing one or more of SXR, CAR or PXR.

Abstract: The invention provides a method of treating an estrogen responsive condition comprising administration of an agonist of an orphan nuclear receptor, wherein activation of the orphan nuclear receptor inhibits estrogen activity. The invention also provides a method of reducing the size of an estrogen responsive tumor comprising administration of an agonist of an orphan nuclear receptor, wherein activation of the orphan nuclear receptor inhibits estrogen activity. The invention also provides a pharmaceutical composition comprising an agonist of an orphan nuclear receptor and a pharmaceutically acceptable vehicle, wherein activation of the orphan nuclear receptor inhibits estrogen activity.

Abstract: In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.

Abstract: A novel nuclear receptor, termed the steroid and xenobiotic receptor (SXR), a broad-specificity sensing receptor that is a novel branch of the nuclear receptor superfamily, has been discovered. SXR forms a heterodimer with RXR that can bind to and induce transcription from response elements present in steroid-inducible cytochrome P450 genes in response to hundreds of natural and synthetic compounds with biological activity, including therapeutic steroids as well as dietary steroids and lipids. Instead of hundreds of receptors, one for each inducing compound, the invention SXR receptors monitor aggregate levels of inducers to trigger production of metabolizing enzymes in a coordinated metabolic pathway. Agonists and antagonists of SXR are administered to subjects to achieve a variety of therapeutic goals dependent upon modulating metabolism of one or more endogenous steroids or xenobiotics to establish homeostasis.

Abstract: In one embodiment, the present invention relates to compounds and compositions including pharmaceutical compositions containing the compounds and associated methods that uncouple sugar-mediated coupling of proteins, lipids, nucleic acids, and other biomaterials, and any combination thereof. In another embodiment, the compositions and associated methods have utility in vivo to reduce the deleterious effects of sugar-mediated coupling processes in an organism, when the organism is exposed to the compound or composition internally, by ingestion, transdermal application, or other means. In yet another embodiment, the compositions and associated methods are useful for the ex-vivo treatment of organs, cells and tissues and external treatment of hair, nails and skin to rejuvenate them by changing deformability and increase the tissue diffusion coefficient. In a further embodiment, the present invention relates to novel compounds and pharmaceutical compositions.